Why did the market react skeptically to your acquisition of Viatris's biosimilar assets?
Replied byKiran Mazumdar-Shaw
Founder & Executive Chairperson at Biocon
Niche: Health & Wellness
Revenue: Approx. $172 Million/month
Location: Bengaluru, Karnataka, India
Started: 1978
The three billion dollar acquisition required us to take on debt, whereas we had previously been debt-free. While the market accepts high debt in massive corporations, they penalized us. We ignored the naysayers, cut the debt, and successfully built a global commercial engine.
0
From the Full Interview
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Share this Answer
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Cite This Answer
Use this answer in your research, article, or academic work
Related Answers
How did your father's liberal worldviews shape your early career decisions?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
How did your friend's battle with cancer influence your work in oncology biosimilars?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose to bypass the Indian market for your first GLP-1 drug launch?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose your niece Claire as your successor at Biocon?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
What was your father's perspective on paying capitation fees to secure a college seat?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
How did you secure your business license during the height of the License Raj?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose to focus on industrial enzymes as your first business venture?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo